Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (21-30 of 721) with videos related to

Pageof 73
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 24, 2021
EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours-the consensus in a nutshellJolanta Kunikowska, Valentina Ambrosini, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
U.S. Imaging Costs: Michal Horný Talks with Ken Herrmann and Johannes Czernin About the Changing Contribution of Medical Imaging to Health Care CostsMichal Horný, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 14, 2025
Precision Medicine Is Critical for the Future of Oncology: Johannes Czernin and Ken Herrmann Talk with Chris Behrenbruch on Theranostics, Imaging, and the Urgency to InnovateChristian Behrenbruch, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2022
Practicing Medicine in Wartime Ukraine: A Conversation Between Yaroslav Kmetyuk, Johannes Czernin, and Ken HerrmannYaroslav Kmetyuk, Johannes Czernin, Ken Herrmann
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|April 9, 2019
Production of [<sup>11</sup>C]Formaldehyde by the XeF<sub>2</sub> mediated oxidation of [<sup>11</sup>C]Methanol and its application in the labeling of α-(N-[<sup>11</sup>C]Methylamino)isobutyric acidMichael Nader, Franz Oberdorfer, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 2022
A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken HerrmannSilke Gillessen, Johannes Czernin, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression CriteriaStefano Fanti, Boris Hadaschik, Ken Herrmann
Med (New York, N.Y.)|April 18, 2025
CD70-targeted cancer theranostics: Progress and challengesWeijun Wei, Viktor Grünwald, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 10, 2014
Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 PatientsJohannes Czernin, Lisa Ta, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2016
18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 PatientsClaudio Spick, Ken Herrmann, Johannes Czernin
Pageof 73

Showing results (21-30 of 721) with videos related to

Sort By:
Pageof 73
European Journal of Nuclear Medicine and Molecular Imaging|February 24, 2021
EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours-the consensus in a nutshellJolanta Kunikowska, Valentina Ambrosini, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
U.S. Imaging Costs: Michal Horný Talks with Ken Herrmann and Johannes Czernin About the Changing Contribution of Medical Imaging to Health Care CostsMichal Horný, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 14, 2025
Precision Medicine Is Critical for the Future of Oncology: Johannes Czernin and Ken Herrmann Talk with Chris Behrenbruch on Theranostics, Imaging, and the Urgency to InnovateChristian Behrenbruch, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2022
Practicing Medicine in Wartime Ukraine: A Conversation Between Yaroslav Kmetyuk, Johannes Czernin, and Ken HerrmannYaroslav Kmetyuk, Johannes Czernin, Ken Herrmann
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|April 9, 2019
Production of [<sup>11</sup>C]Formaldehyde by the XeF<sub>2</sub> mediated oxidation of [<sup>11</sup>C]Methanol and its application in the labeling of α-(N-[<sup>11</sup>C]Methylamino)isobutyric acidMichael Nader, Franz Oberdorfer, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 2022
A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken HerrmannSilke Gillessen, Johannes Czernin, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression CriteriaStefano Fanti, Boris Hadaschik, Ken Herrmann
Med (New York, N.Y.)|April 18, 2025
CD70-targeted cancer theranostics: Progress and challengesWeijun Wei, Viktor Grünwald, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 10, 2014
Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 PatientsJohannes Czernin, Lisa Ta, Ken Herrmann
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2016
18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 PatientsClaudio Spick, Ken Herrmann, Johannes Czernin
Pageof 73